Here are the DEF 14A proxy statements from Integra LifeSciences Holdings (IART) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow IART and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IART filings page.
Integra LifeSciences Holdings Corporation is asking stockholders to elect eight directors, ratify PricewaterhouseCoopers LLP, approve executive compensation on an advisory basis, and adopt an amendment to its 2003 Equity Incentive Plan at the 2026 annual meeting.
For 2025, Integra reported $1.64 billion in revenue, up 1.5%, driven by Codman Specialty Surgical growth, but recorded a GAAP net loss of $516.5 million as it invested heavily in quality systems, supply chain reliability and facility upgrades. Adjusted EBITDA was $317.5 million with operating cash flow of $50 million. The company highlights progress on an enterprise transformation, product relaunches such as PriMatrix and Durepair, new neurosurgical technologies, and ongoing work to resolve FDA-related quality commitments while embedding broader corporate sustainability and governance practices.